Based on the findings of the current study, the expression of ERα or TGFBR1 in the kidney can feasibly be altered to reduce the activation of the SMAD pathway, thereby reducing the production of inflammatory mediators in the context of renal fibrosis. Here, TGFBR1 is linked to renal fibrosis.